(Reuters) – Drugs used for treating arthritis are being tested as treatments for COVID-19, the disease caused by a new coronavirus, as researchers rush to find ways of helping patients and slowing the number of infections. Sanofi and Regeneron Pharmaceuticals ... More »
(Reuters) – The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc’s treatment for a second rare blood disorder, the company said. The treatment, Ultomiris, has already been approved in the United States, Japan and the European Un... More »
(Reuters) – The U.S. patent office will review patents on Alexion Pharmaceuticals Inc’s blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday. The move deals a blow to Alexion’s efforts to ward off competition for it... More »
(Reuters) – The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc’s rare blood disorder drug Ultomiris, an early backing that also solidifies the company’s dominant market position. The company’s flagship drug, Soliris, was the l... More »
(Reuters) – Vertex Pharmaceuticals Inc topped analysts’ forecasts for quarterly profit on Thursday, led by stronger-than expected sales of its latest cystic fibrosis drug as well as double-digit growth in sales of older treatments. Boston-based Vertex, like ot... More »
FILE PHOTO: French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016. REUTERS/Philippe Wojazer/File Photo (Reuters) – A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi s... More »
(Reuters) – Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients. Since the approvals in 2015 o... More »
(Reuters) – The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday. All ongoing studies of the drug, fitusiran, had been pla... More »
Torrent Pharmaceuticals said on Friday it would buy more than 120 brands from Unichem Laboratories in India and Nepal, and its manufacturing plant at Sikkim. More »
Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta. More »
Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study. More »
Sanofi and Regeneron's biotech drug dupilumab scored a hit in treating severe asthma, clinical trial data showed on Monday, raising competition in an expected multibillion-dollar market. More »
Inotek Pharmaceuticals Corp said on Friday it would evaluate strategic options after its sole experimental eye drug failed another trial, sending the company’s shares tumbling 45 percent in extended trading. More »
France’s Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and high cholesterol. More »
An Amgen sign is seen at the company’s office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival ... More »
Corbus Pharmaceuticals Holdings Inc said its lead drug outperformed a placebo in a mid-stage study involving patients with a form of systemic sclerosis, an incurable autoimmune condition caused by abnormal growth of connective tissue. More »
NEW YORK Embattled drug company Valeant Pharmaceuticals International Inc, whose stock price has tumbled 38 percent this year, will appoint three new board members as soon as Wednesday, people familiar with the matter said on Tuesday. The drug maker will award... More »
NEW YORK Billionaire investor Bill Ackman on Tuesday called embattled drug company Valeant Pharmaceuticals a “very valuable asset” but forecast that if the company’s situation does not stabilize soon new management will be brought in or the company will be sol... More »
